Photography exhibit features breast and ovarian cancer patients and families

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Photography exhibit features breast and ovarian cancer patients and families

Articles in this issue
Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
Chemotherapy Results in Greater Pain/Fatigue Vs Endocrine Therapy in Breast Cancer
Chemotherapy Results in Greater Pain/Fatigue Vs Endocrine Therapy in Breast Cancer
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Tamoxifen Shows No Notable Long-Term Physical Health Decline in BC Survivors
Tamoxifen Shows No Notable Long-Term Physical Health Decline in BC Survivors
ET Shows Favorable Physical Health Decline Data vs Chemo in Breast Cancer
ET Shows Favorable Physical Health Decline Data vs Chemo in Breast Cancer
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
42nd Annual Miami Breast Cancer Conference: The Show and After Show
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
Related Content
PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

Tim Cortese
April 8th 2025
Article

Palbociclib with endocrine therapy did not improve outcomes in HR-positive, HER2-negative breast cancer, but improved invasive DFS in lobular disease.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

Crucial Answers on Long-Term Physical Health Effects From Breast Cancer Treatments

Crucial Answers on Long-Term Physical Health Effects From Breast Cancer Treatments

Tim Cortese
March 24th 2025
Article

Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.